Aptatek Biosciences is a clinical-stage diagnostics company and Columbia University spinout developing aptamer-enabled technologies for decentralized metabolic monitoring. Its lead investigational program, PheCheck, is an at-home system for quantitative phenylalanine monitoring in people with phenylketonuria (PKU), built on the HomeCheck aptamer-based sensing platform. PheCheck has received US FDA Breakthrough Device Designation and is in a multi-site clinical study expected to complete before the end of 2026, supporting a planned FDA regulatory submission.
1
Round
1
Industry
4
Tags
Sep 29, 2026
Latest raise
Funding activity · 1 round
Sep 29, 2026
$-1
Undisclosed
Led by Canterbury Scientific Ltd
Article coming soon.
Pricing
Public hubs orient you on the raise. Paid plans unlock live AI adoption signals across your market.
For individuals and small teams getting started with AI buyer intelligence.
$149
/month
Features
For outbound teams and agencies that need more coverage and faster signal cadence.
$249
/month
Features
Act on this raise
Funding is the starting point. VeilStrat shows whether capital is showing up as hiring, tools, and web activity you can sell into.
